Mediterranean Oncology Association: A Decade of Collaboration and Care

The AROME Association, established over ten years ago, is committed to enhancing cancer care among oncologists in the Mediterranean region. This initiative focuses on optimizing patient treatment through collaborative efforts and a deep understanding of regional needs, particularly concerning cancer epidemiology.

Understanding Regional Disparities: Low vs High Income Countries

In discussing cancer incidence, it’s imperative to recognize the significant differences between low/middle-income countries (LMIC) and high-income countries (HIC). In the interview, Joseph Gligorov, President of the Mediterranean Oncology Association (AROME), highlights critical findings from recent studies. These studies underscore that advanced-stage cancers are significantly more prevalent in low/middle-income countries (LMICs) compared to high-income countries (HICs). This insight emphasizes the urgent need for tailored cancer care strategies and improved healthcare access in LMICs. This disparity underscores the necessity for tailored treatment strategies across different regions.

While both affluent and less developed nations require essential treatments for curable diseases, LMICs often face challenges with metastatic conditions due to limited access to high-cost medications needed for such cases.

Strategic Investment: Balancing Early Detection and Treatment

Investing exclusively in drugs for metastatic diseases is impractical. A more balanced approach involves prioritizing early cancer detection and screening programs. Early diagnosis plays a crucial role by reducing the reliance on expensive treatments and aggressive interventions, allowing patients to benefit from simpler and less costly treatment options.

Dual Strategy for Effective Cancer Management in LMICs

To effectively tackle these challenges, it’s essential to implement a two-pronged strategy:

1. Increase Prevention Efforts: Focus on preventive measures to lower the incidence of advanced-stage cancers, thereby reducing associated healthcare costs.
2. Enhance Access to Essential Medications: Improve the availability of crucial drugs for patients in LMICs to enhance their life expectancy and quality of life.

Article based on an exclusive interview with Dr Jean-Philippe Minart, Cannes, France